We have reached the first position, in December 2019, in the international inclusion of patients in the trial with sublingual apomorphine and motor blocks in Parkinson.
We are also leading the national inclusion of patients in the Clarity AD trial (monoclonal anti-amyloid antibody in early Alzheimer)
Finally, in the Graduate trial (monoclonal subcutaneous in Alzheimer) we are the second recruitment site in our country.
